Cingulate (CING) Cash from Financing Activities (2021 - 2025)
Cingulate's (CING) quarterly Cash from Financing Activities came in at $8.6 million in Q4 2025, up 33.17% YoY from $6.4 million in Q4 2024, and up 348.25% on a QoQ basis from $1.9 million in Q1 2025.
Cingulate (CING) Cash from Financing Activities (2021 - 2025) Analysis & Trends
Cingulate (CING) has 5 years of Cash from Financing Activities data on file, last reported at $8.6 million in Q4 2025.
- Quarterly Cash from Financing Activities rose 33.17% year-over-year to $8.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $30.4 million (down 1.51% YoY) and the FY2025 annual result came in at $16.1 million, down 47.6% from the prior year.
- Cash from Financing Activities rose to $8.6 million in Q4 2025, from $1.9 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $19.9 million in Q4 2021 to a low of -$89780.0 in Q4 2022.
- A 5-year average of $4.6 million and a median of $2.6 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 100.45% — and 2024, when it surged 252377.63%.
- Tracing CING's Cash from Financing Activities over 5 years: stood at $19.9 million in 2021, then plunged by 100.45% to -$89780.0 in 2022, then jumped by 1008.26% to $815434.0 in 2023, then surged by 690.89% to $6.4 million in 2024, then surged by 33.17% to $8.6 million in 2025.
- The last three Cash from Financing Activities figures came in at $8.6 million (Q4 2025), $1.9 million (Q1 2025), and $6.4 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | -273.15 Mn |
| 10 | Cingulate | 72.52 Mn | 72.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.59 Mn |
| Dec 31, 2025 | 8.59 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Dec 31, 2024 | 6.45 Mn |
| Dec 31, 2024 | 6.45 Mn |
| Sep 30, 2024 | 13.40 Mn |
| Sep 30, 2024 | 13.40 Mn |
| Jun 30, 2024 | 1.08 Mn |
| Jun 30, 2024 | 1.08 Mn |
| Mar 31, 2024 | 9.89 Mn |
| Mar 31, 2024 | 9.89 Mn |
| Dec 31, 2023 | 815,434.00 |
| Dec 31, 2023 | 815,434.00 |
| Sep 30, 2023 | 5.93 Mn |
| Sep 30, 2023 | 5.93 Mn |
| Jun 30, 2023 | 3.21 Mn |
| Jun 30, 2023 | 3.21 Mn |
| Mar 31, 2023 | -3,920.00 |
| Mar 31, 2023 | -3,920.00 |